Allergology Berlin Germany

DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1, , , , , , et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023; 78(5): 1269–1279. 2. Kit and melanocyte migration. J Invest Dermatol. 2006; 126(5): 945–947. 3, , , , . Stage-specific localization and expression of c-kit in the adult human testis. J Histochem Cytochem.

Filename Description all70199-sup-0001-TableS1-S3-FigureS1.docxWord 2007 document , 175.5 KB Table S1: Participating CURE centers contributing to this analysis. Table S2: Sensitivity analysis based on a comparison of baseline age, disease duration, disease activity scores, and use of sgH1-AH between patients who had data at follow-up versus those who did not have these data. Table S3: Treatment patterns based on UCT score at baseline and follow-up. Figure S1: Data analysis flow chart.